'AHA Urges HRSA To Take Immediate Enforcement Action To Block J&J's Illegal Imposition Of 340B Rebate Model' - American Hospital Association
Portfolio Pulse from Benzinga Newsdesk
The American Hospital Association (AHA) is urging the Health Resources and Services Administration (HRSA) to take enforcement action against Johnson & Johnson (J&J) for changing its 340B Drug Pricing Program model. J&J plans to replace upfront discounts with a rebate model for drugs like Stelara and Xarelto, potentially impacting hospital finances and patient access.
August 28, 2024 | 5:33 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Johnson & Johnson is facing criticism from the AHA for altering its 340B Drug Pricing Program model, moving from upfront discounts to a rebate system. This change could lead to financial strain on hospitals and affect patient access to drugs like Stelara and Xarelto.
The AHA's strong opposition and call for HRSA enforcement suggest potential regulatory challenges for J&J. The shift to a rebate model could strain hospital finances and disrupt drug access, leading to negative sentiment and potential short-term stock pressure.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100